Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Phosphodiesterase type 5 inhibitors’ extended duration of response as a variable in the treatment of erectile dysfunction

International Journal of Impotence Research volume 19, pages 119–123 (2007)Cite this article

A Corrigendum to this article was published on 01 March 2007

Abstract

The phosphodiesterase type 5 (PDE5) inhibitors, sildenafil, tadalafil and vardenafil, are a class of medications that are safe and effective in treating erectile dysfunction (ED). Yet, resuming sexual activity following a period of abstinence in response to ED may be anxiety-provoking for the man, his partner and their relationship, causing the sexual encounter to become a stressful event. The differences between PDE5 inhibitors in terms of duration of action can be successfully utilized by healthcare professionals to mitigate some of the psychosocial barriers that interfere with treating ED. PDE5 inhibitors with a longer duration of responsiveness provide some men with ED and their partners, a treatment option that may offer greater flexibility and potentially less anxiety surrounding the resumption of sexual activity. Shorter-acting PDE5s may be preferred by men/couples with predictable sexual scripts, excellent communication strategies and concerns regarding the duration of side effects.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Riley A . The role of the partner in erectile dysfunction and its treatment. Int J Impot Res 2002; 14 (Suppl 1): S105–S109.

    Article  PubMed  Google Scholar 

  2. Lue TF, Basson R, Giuliano F, Montorsi F, Rosen R . Summary of the recommendations on sexual dysfunctions in men. In: Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F (eds). Sexual Medicine: Sexual Dysfunctions in Men and Women. Health Publications: Paris, 2004, pp 605–619.

    Google Scholar 

  3. Swindle RW, Cameron AE, Lockhart DC, Rosen RC . The psychological and interpersonal relationship scales: assessing the psychological and relationship outcomes associated with erectile dysfunction and its treatment. Arch Sex Behav 2004; 33: 19–30.

    Article  PubMed  Google Scholar 

  4. Viagra® (sildenafil) Prescribing Information. Pfizer Inc: New York, NY, 2005.

  5. Levitra® (vardenafil) Prescribing Information. Bayer Pharmaceuticals Corp: West Haven, CT, 2005.

  6. Cialis® (tadalafil) Prescribing Information. Lilly ICOS LLC: Indianapolis, IN and Bothell, WA, 2005.

  7. Latini DM, Penson DF, Lubeck DP, Wallace KL, Henning JM, Lue TF . Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction study. J Urol 2003; 169: 1437–1442.

    Article  PubMed  Google Scholar 

  8. Althof SE . Quality of life and erectile dysfunction. Urology 2002; 59: 803–810.

    Article  PubMed  Google Scholar 

  9. Althof SE . When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res 2002; 14 (Suppl 1): S99–S104.

    Article  PubMed  Google Scholar 

  10. Son H, Park K, Kim SW, Paick JS . Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2004; 6: 117–120.

    CAS  PubMed  Google Scholar 

  11. Althof SE, Wieder M . Psychotherapy for erectile dysfunction: now more relevant than ever. Endocrine 2004; 23: 131–134.

    Article  CAS  PubMed  Google Scholar 

  12. Dunn ME . Restoration of couple's intimacy and relationship vital to reestablishing erectile function. J Am Osteopathol Assoc 2004; 104 (Suppl 4): S6–S10.

    Google Scholar 

  13. Perelman MA . Sex coaching for physicians: combination treatment for patient and partner. Int J Impot Res 2003; 15 (Suppl 5): S67–S74.

    Article  PubMed  Google Scholar 

  14. Althof SE . Therapeutic weaving: the integration of treatment techniques. In: Levine S (ed). Handbook of Clinical Sexuality for Mental Health Professionals. Brunner-Routledge: New York, 2003, pp 359–376.

    Google Scholar 

  15. Perelman M . Combination therapy: integration of sex therapy and pharmacotherapy. In: Balon R, Seagraves R (eds). Handbook of Sexual Dysfunction. Marcel Dekker: New York, 2005, pp 13–41.

    Google Scholar 

  16. Seftel AD . Challenges in oral therapy for erectile dysfunction. J Androl 2002; 23: 729–736.

    PubMed  Google Scholar 

  17. Eardley I, Ellis P, Boolell M, Wulff M . Onset and duration of action of sildenafil citrate for the treatment of erectile dysfunction. Br J Clin Pharmacol 2002; 53: 61S–65S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Moncada I, Jara J, Subira D, Castano I, Hernandez C . Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol 2004; 46: 357–361.

    Article  CAS  PubMed  Google Scholar 

  19. Stief C, Valiquette L, Montorsi F, Hellstrom WJG, Giuliano F, Homering M et al. Vardenafil (Levitra®) improves maintenance success rates from 15 min to up to 12 hours from time of dosing to start of sexual activity. Abstract presented at: 4th Congress on the Aging Male; February 26–29, 2004; Prague.

  20. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R . Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121–126.

    Article  PubMed  Google Scholar 

  21. Shabsigh R . Therapy of ED: PDE-5 inhibitors. Endocrine 2004; 23: 135–141.

    Article  CAS  PubMed  Google Scholar 

  22. Del Popolo G, Li Marzi V, Mondaini N, Lombardi G . Time/duration effectiveness of sildenafil versus tadalafil in the treatment of erectile dysfunction in male spinal cord-injured patients. Spinal Cord 2004; 42: 643–648.

    Article  CAS  PubMed  Google Scholar 

  23. Shabsigh R, Burnett AL, Eardley I, Sharlip ID, Ellsworth PI, Garcia CS et al. Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials. BJU Int 2005; 96: 857–863.

    Article  CAS  PubMed  Google Scholar 

  24. Perelman MA . Psychosocial evaluation and combination treatment of men with erectile dysfunction. Urol Clin North Am 2005; 32: 431–445.

    Article  PubMed  Google Scholar 

  25. Althof SE, Dunn M, Perelman M . Expert Panel Recommendations for Optimizing Treatment of ED: The Effects of Duration of Responsiveness of PDE5 Inhibitors on the Restoration of Sexual Functioning [Roundtable Discussion]. Lilly ICOS LLC: Indianapolis, IN and Bothell, WA, 2004.

    Google Scholar 

  26. Cappelleri JC, Bell SS, Althof SE, Siegel RL, Stecher VJ . Comparison between sildenafil-treated subjects with erectile dysfunction and control subjects on the Self-Esteem and Relationship questionnaire. J Sex Med 2006; 3: 274.

    Article  CAS  PubMed  Google Scholar 

  27. Althof SE, Leiblum SR, Chevert-Measson M, Hartman U, Levine SB, McCabe M et al. Psychological and interpersonal dimensions of sexual function and dysfunction. In: Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F (eds). Sexual Medicine: Sexual Dysfunctions in Men and Women. Health Publications: Paris, 2004, pp 73–116.

    Google Scholar 

  28. Fisher W, Rosen RC, Eardley I, Sand M, Goldstein I . Sexual experience of female partners of men with erectile dysfunction: the Female Experience of Men's Attitudes to Life Events and Sexuality (FEMALES) study. J Sex Med 2005; 2: 615.

    Google Scholar 

  29. Tiefer L, Schuetz-Mueller D . Psychological issues in diagnosis and treatment of erectile disorders. Urol Clin North Am 1995; 22: 767–773.

    CAS  PubMed  Google Scholar 

  30. Chun J, Carson III CC . Physician–patient dialogue and clinical evaluation of erectile dysfunction. Urol Clin North Am 2001; 28: 249–250.

    Article  CAS  PubMed  Google Scholar 

  31. Klotz T, Mathers M, Klotz R, Sommer F . Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra®)? Int J Impot Res 2005; 17: 2–4.

    Article  CAS  PubMed  Google Scholar 

  32. Sadovsky R, Dunn M, Grobe BM . Erectile dysfunction: the primary care practitioner's view. Am J Manage Care 1999; 5: 333–341.

    CAS  Google Scholar 

  33. Hinchcliff S, Gott M . Perceptions of well-being in sexual ill health: what role does age play? J Health Psychol 2004; 9: 649–660.

    Article  Google Scholar 

  34. Carson C, Giuliano F, Goldstein I, Hellstrom W, Lue T, Montorsi F et al. The ‘effectiveness’ scale – therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. Int J Impot Res 2004; 16: 207–213.

    Article  CAS  PubMed  Google Scholar 

  35. Shabsigh R, Kimoto Y, Amar E, Hackett G, Jarow JP, Mirone V et al. Economical aspects of sexual dysfunctions. In: Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F (eds). Sexual Medicine: Sexual Dysfunctions in Men and Women. Health Publications: Paris, 2004, pp 141–160.

    Google Scholar 

  36. Dunn ME . Psychological perspectives of sex and aging. Am J Cardiol 1988; 61: 24H–26H.

    Article  CAS  PubMed  Google Scholar 

  37. Hatzichristou DG, Apostolidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A . Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol 2000; 164: 1197–1200.

    Article  CAS  PubMed  Google Scholar 

  38. El-Galley R, Rutland H, Talic R, Keane T, Clark H . Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 2001; 166: 927–931.

    Article  CAS  PubMed  Google Scholar 

  39. Fisher WA, Rosen RC, Eardley I, Niederberger C, Nadel A, Kaufman J et al. The Multinational Men's Attitudes to Life Events and Sexuality (MALES) study phase II: understanding PDE5 inhibitor treatment seeking patterns among men with erectile dysfunction. J Sex Med 2004; 1: 150–160.

    Article  PubMed  Google Scholar 

  40. Montorsi F, Verheyden B, Meuleman E, Junemann K-P, Moncada I, Valiquette L et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45: 339–345.

    Article  CAS  PubMed  Google Scholar 

  41. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96: 313–321.

    Article  PubMed  Google Scholar 

  42. Kalsi JS, Kell PD . Update on oral treatments for male erectile dysfunction. J Eur Acad Dermatol Venereol 2004; 18: 267–274.

    Article  CAS  PubMed  Google Scholar 

  43. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson K-E, Althof S et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2003; 1: 6–23.

    Article  Google Scholar 

  44. Hatzichristou D, Rosen RC, Broderick G, Clayton A, Cuzin B, Derogatis L et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004; 1: 49–60.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Center for Human Sexuality, State University of New York, Downstate Medical Center, Brooklyn, NY, USA

    M E Dunn, S E Althof & M A Perelman

Authors
  1. M E Dunn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S E Althof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M A Perelman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M E Dunn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dunn, M., Althof, S. & Perelman, M. Phosphodiesterase type 5 inhibitors’ extended duration of response as a variable in the treatment of erectile dysfunction. Int J Impot Res 19, 119–123 (2007). https://doi.org/10.1038/sj.ijir.3901490

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901490

Keywords

This article is cited by

Search

Advanced search

Quick links